期刊文献+

白细胞介素-1阻滞剂在心血管疾病中的研究进展

Research progress of interleukin-1 blockers in cardiovascular diseases
下载PDF
导出
摘要 白细胞介素-1作为先天免疫系统的关键细胞因子在心血管疾病中的作用逐渐显现。阻断白细胞介素-1已被证明在其他心血管疾病中有效,如心肌炎、心律失常和心力衰竭。本综述旨在总结白细胞介素-1阻滞剂在心血管疾病中的作用,简要描述其发病机理及相关的临床研究。阻断白细胞介素-1通路可能是一种新的治疗策略,可能成为许多急慢性心血管疾病的治疗方法。 Interleukin-1, as a key cytokine of innate immune system, is playing an increasingly important role in cardiovascular diseases. Blocking interleukin-1 has proved to be effective in other cardiovascular diseases, such as myocarditis, arrhythmia, and heart failure. This review aims to summarize the role of interleukin-1 blockers in cardiovascular disease, and briefly describe its pathogenesis and related clinical studies. Blocking the interleukin-1 pathway may be a new therapeutic strategy and may become a treatment for many acute and chronic cardiovascular diseases.
作者 蒋小眉 谭华清 秧茂盛 唐湘宇 JIANG Xiao-mei;TAN Hua-qing;YANG Mao-sheng;TANG Xiang-yu(Jishou University School of Medicine,Hu′nan Province,Jishou 416000,China;The Eighteenth Ward,Department of Cardiology,Loudi Central Hospital,Hu′nan Province,Loudi 417000,China)
出处 《中国当代医药》 2019年第35期17-21,共5页 China Modern Medicine
基金 湖南省临床医疗技术创新引导项目(2017SK51209)
关键词 白细胞介素-1 阿那白滞素 卡那单抗 心包炎 动脉粥样硬化 心血管疾病 Interleukin-1 Anakinra Canakinumab Pericarditis Atherosclerosis Cardiovascular disease
  • 相关文献

参考文献1

二级参考文献17

  • 1Rajamaki K,Lappalainen J,Oorni K,et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation [J]. PLoS One,2010,5(7):11765.
  • 2Duewell P,Kono H,Raynet KJ,et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals [J]. Nature,2010,464(7293) : 1357-1361.
  • 3Fearon WF, Fearon DT. Inflammation and cardiovascular disease: role of the interleukin-1 receptor antagonist [J]. Circulation, 2008, 117 (20) : 2577-2579.
  • 4Olofsson PS,Sheikine Y,Jatta K, et al. A functional interleukin-I receptor antagonist polymorphism influences atherosclerosis de- velopment. The interleukin-lbeta: interleukin-1 receptor antago- nist balance in atheroselerosis[J]. Circ J,2009,73(8): 1531-1536.
  • 5Neri M,Fineschi V,Di Paolo M,et al. Cardiac Oxidative Stress and Inflammatory Cytokines Response After Myocardia! Infarction [J]. Curt Vasc Pharmacol,2013,29. [Epub ahead of print].
  • 6Boni-Schnetzler,Thorne J,Parnaud G,et al3ncreased interleukin (IL)-lbeta messenger ribonucleic acid expression in beta-cells of individuals with type 2 diabetes and regulation of IL-1 beta in human islet by glucose and autostimulation [J]. J Clin End0crinol Metah, 2008,93 (10) : 4065-4074.
  • 7Aksentijevich I, Masters SL, Ferguson PJ,et al. An autoinflamma- tory disease with deficiency of the interleukin-l-recepfor antago- nist[J]. N Engl J Med, 2009,360(23) : 2426-2437.
  • 8Reddy S,Jia S,Geoffrey R,et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus [J]. N Engl J Med, 2009,360(10) : 2438-2444.
  • 9Grothusen C,Hagemann A,Attmann T,et al. Impact of an inter- leukin-1 receptor antagonist and erythropoietin on experimental myocardial ischemia/reperfusion injury[J]. Scientific World Jour- nal,2012,2012(10) :737585.
  • 10Toldo S,Schatz AM,Mezzaroma E,et al. Recombinant human interleukin-1 receptor antagonist provides cardioprotecon dur-ing myocardial ischemia reperfusion in the mouse [J]. Cardio- vasc Drugs Ther,2012,26(3) :273-276.

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部